[go: up one dir, main page]

EE200300333A - Mittekristallilise kaltsiumatorvastatiini valmistamismeetod - Google Patents

Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Info

Publication number
EE200300333A
EE200300333A EEP200300333A EEP200300333A EE200300333A EE 200300333 A EE200300333 A EE 200300333A EE P200300333 A EEP200300333 A EE P200300333A EE P200300333 A EEP200300333 A EE P200300333A EE 200300333 A EE200300333 A EE 200300333A
Authority
EE
Estonia
Prior art keywords
atorvastatin
crystalline
calcium
oratorvastatin
preparation
Prior art date
Application number
EEP200300333A
Other languages
English (en)
Inventor
Sorsak Gorazd
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of EE200300333A publication Critical patent/EE200300333A/et
Publication of EE05270B1 publication Critical patent/EE05270B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300333A 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod EE05270B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium

Publications (2)

Publication Number Publication Date
EE200300333A true EE200300333A (et) 2003-10-15
EE05270B1 EE05270B1 (et) 2010-02-15

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300333A EE05270B1 (et) 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Country Status (27)

Country Link
US (2) US6750353B2 (et)
EP (1) EP1373202B1 (et)
JP (1) JP4336106B2 (et)
KR (1) KR100882066B1 (et)
CN (1) CN1260213C (et)
AT (1) ATE294159T1 (et)
AU (1) AU2002219455B2 (et)
BG (1) BG108017A (et)
BR (1) BR0206637A (et)
CA (1) CA2435954C (et)
CZ (1) CZ20031988A3 (et)
DE (1) DE60203894T2 (et)
DK (1) DK1373202T3 (et)
EE (1) EE05270B1 (et)
ES (1) ES2240748T3 (et)
HR (1) HRP20030575B1 (et)
HU (1) HU227535B1 (et)
IL (2) IL157068A0 (et)
MX (1) MXPA03006548A (et)
PL (1) PL209428B1 (et)
RS (1) RS51010B (et)
RU (1) RU2324679C2 (et)
SI (2) SI20814A (et)
SK (1) SK286593B6 (et)
UA (1) UA73829C2 (et)
WO (1) WO2002059087A1 (et)
ZA (1) ZA200305307B (et)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
DE60137364D1 (de) 2000-12-27 2009-02-26 Teva Pharma Kristalline formen von atorvastatin
WO2002068335A2 (en) * 2001-02-27 2002-09-06 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
MXPA03010266A (es) 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
WO2005033078A1 (en) * 2003-10-07 2005-04-14 Biocon Limited Process for the production of atorvastatin calcium
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
CA2475123A1 (en) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
SK50112006A3 (sk) 2003-07-02 2006-05-04 Egis Gy�Gyszergy�R Rt. Spôsob prípravy amorfnej formy liečiva - inhibítora zrážania krvných doštičiek
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
AU2004309313A1 (en) * 2003-12-29 2005-07-14 Lek Pharmaceuticals D.D. Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
EP2540704B1 (en) 2004-05-05 2019-07-03 Pfizer Products Inc. Benethamine salt forms of atorvastatin
CA2833770A1 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D Oxidative degradation products of atorvastatin calcium
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
CA2578722C (en) * 2004-08-27 2010-02-02 Biocon Limited Process for atorvastatin calcium amorphous
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20090099371A1 (en) * 2006-01-31 2009-04-16 Runjhun Gupta Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CA2702903C (en) * 2007-10-17 2016-01-19 Todd F. Ovokaitys Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法
WO2022126109A1 (en) 2020-12-08 2022-06-16 Ovokaitys Todd Frank Methods and systems for increased production of stem cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
EP0848705B1 (en) 1995-07-17 2001-11-07 Warner-Lambert Company Crystalline r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (et) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
ATE294159T1 (de) 2005-05-15
HUP0302797A3 (en) 2009-09-28
SK286593B6 (sk) 2009-01-07
CZ20031988A3 (cs) 2003-11-12
JP4336106B2 (ja) 2009-09-30
UA73829C2 (en) 2005-09-15
HRP20030575A2 (en) 2005-06-30
IL157068A0 (en) 2004-02-08
MXPA03006548A (es) 2004-10-15
SK9082003A3 (en) 2003-12-02
AU2002219455B2 (en) 2007-04-26
US20040072895A1 (en) 2004-04-15
CA2435954A1 (en) 2002-08-01
ZA200305307B (en) 2004-07-09
HU227535B1 (en) 2011-08-29
JP2005503997A (ja) 2005-02-10
CN1487921A (zh) 2004-04-07
BR0206637A (pt) 2004-08-03
ES2240748T3 (es) 2005-10-16
PL361763A1 (en) 2004-10-04
US20030109569A1 (en) 2003-06-12
YU56803A (sh) 2006-05-25
KR100882066B1 (ko) 2009-02-10
DE60203894D1 (de) 2005-06-02
CN1260213C (zh) 2006-06-21
EP1373202B1 (en) 2005-04-27
CA2435954C (en) 2008-06-03
PL209428B1 (pl) 2011-08-31
SI1373202T1 (sl) 2005-12-31
WO2002059087A1 (en) 2002-08-01
RS51010B (sr) 2010-10-31
RU2324679C2 (ru) 2008-05-20
HUP0302797A2 (hu) 2003-11-28
DE60203894T2 (de) 2006-01-19
RU2003124962A (ru) 2005-01-10
BG108017A (bg) 2004-08-31
IL157068A (en) 2009-09-01
SI20814A (sl) 2002-08-31
US6750353B2 (en) 2004-06-15
DK1373202T3 (da) 2005-05-17
HRP20030575B1 (hr) 2011-10-31
KR20030077003A (ko) 2003-09-29
EP1373202A1 (en) 2004-01-02
EE05270B1 (et) 2010-02-15
US7074940B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
EE200300333A (et) Mittekristallilise kaltsiumatorvastatiini valmistamismeetod
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
WO2004062601A3 (en) Antibacterial agents
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
WO2004096823A3 (en) Novel ketolide derivatives
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
ES2307511T3 (es) Derivados de eritromicina c-2 modificados.
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
CA2393757A1 (en) Cycloamine ccr5 receptor antagonists
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
AP2002002679A0 (en) Novel polymorph V of torasemide.
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.
TNSN05247A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2005051349A3 (en) Pharmaceutical compositions of mirtazapine
WO2025162289A3 (zh) 一种pde4b抑制剂的晶型及其在医药上的用途

Legal Events

Date Code Title Description
HB1A Correction of owner name or address
HC1A Change of owner name
HC1A Change of owner name
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130122